Role of Lysine‐Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia‐Inducible Factor 1α and E2F1

Objective Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which t...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 74; no. 6; pp. 948 - 960
Main Authors Doi, Kohei, Murata, Koichi, Ito, Shuji, Suzuki, Akari, Terao, Chikashi, Ishie, Shinichiro, Umemoto, Akio, Murotani, Yoshiki, Nishitani, Kohei, Yoshitomi, Hiroyuki, Fujii, Takayuki, Watanabe, Ryu, Hashimoto, Motomu, Murakami, Kosaku, Tanaka, Masao, Ito, Hiromu, Park‐Min, Kyung‐Hyun, Ivashkiv, Lionel B., Morinobu, Akio, Matsuda, Shuichi
Format Journal Article
LanguageEnglish
Published Boston, USA Wiley Periodicals, Inc 01.06.2022
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN2326-5191
2326-5205
2326-5205
DOI10.1002/art.42074

Cover

Abstract Objective Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine‐specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis. Methods LSD1‐specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14‐positive monocytes, with subsequent assessment by RNA‐sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis‐acting expression quantitative trait loci (cis‐eQTL) were analyzed for association with the expression of hypoxia‐inducible factor 1α (HIF‐1α), and associations between HIF‐1α allelic variants and extent of bone erosion were evaluated. Results In human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin–dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1‐mediated hypoxia and cell‐cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF‐1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL‐stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF‐1α protein, thereby promoting glycolysis, in conjunction with up‐regulation of the transcription factor E2F1. Analyses of cis‐eQTL revealed that higher HIF‐1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis. Conclusion LSD1 metabolically regulates osteoclastogenesis in an energy‐demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA.
AbstractList ObjectiveHypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine‐specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis.MethodsLSD1‐specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14‐positive monocytes, with subsequent assessment by RNA‐sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis‐acting expression quantitative trait loci (cis‐eQTL) were analyzed for association with the expression of hypoxia‐inducible factor 1α (HIF‐1α), and associations between HIF‐1α allelic variants and extent of bone erosion were evaluated.ResultsIn human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin–dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1‐mediated hypoxia and cell‐cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF‐1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL‐stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF‐1α protein, thereby promoting glycolysis, in conjunction with up‐regulation of the transcription factor E2F1. Analyses of cis‐eQTL revealed that higher HIF‐1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis.ConclusionLSD1 metabolically regulates osteoclastogenesis in an energy‐demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA.
Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine-specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis.OBJECTIVEHypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine-specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis.LSD1-specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14-positive monocytes, with subsequent assessment by RNA-sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis-acting expression quantitative trait loci (cis-eQTL) were analyzed for association with the expression of hypoxia-inducible factor 1α (HIF-1α), and associations between HIF-1α allelic variants and extent of bone erosion were evaluated.METHODSLSD1-specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14-positive monocytes, with subsequent assessment by RNA-sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis-acting expression quantitative trait loci (cis-eQTL) were analyzed for association with the expression of hypoxia-inducible factor 1α (HIF-1α), and associations between HIF-1α allelic variants and extent of bone erosion were evaluated.In human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin-dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1-mediated hypoxia and cell-cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF-1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL-stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF-1α protein, thereby promoting glycolysis, in conjunction with up-regulation of the transcription factor E2F1. Analyses of cis-eQTL revealed that higher HIF-1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis.RESULTSIn human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin-dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1-mediated hypoxia and cell-cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF-1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL-stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF-1α protein, thereby promoting glycolysis, in conjunction with up-regulation of the transcription factor E2F1. Analyses of cis-eQTL revealed that higher HIF-1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis.LSD1 metabolically regulates osteoclastogenesis in an energy-demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA.CONCLUSIONLSD1 metabolically regulates osteoclastogenesis in an energy-demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA.
Objective Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine‐specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis. Methods LSD1‐specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14‐positive monocytes, with subsequent assessment by RNA‐sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis‐acting expression quantitative trait loci (cis‐eQTL) were analyzed for association with the expression of hypoxia‐inducible factor 1α (HIF‐1α), and associations between HIF‐1α allelic variants and extent of bone erosion were evaluated. Results In human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin–dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1‐mediated hypoxia and cell‐cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF‐1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL‐stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF‐1α protein, thereby promoting glycolysis, in conjunction with up‐regulation of the transcription factor E2F1. Analyses of cis‐eQTL revealed that higher HIF‐1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis. Conclusion LSD1 metabolically regulates osteoclastogenesis in an energy‐demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA.
Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates inflammatory responses and increases bone resorption in inflammatory arthritis by enhancing osteoclastogenesis. The mechanism by which the hypoxia response is linked to osteoclastogenesis and inflammatory bone resorption is unclear. This study was undertaken to evaluate whether the protein lysine-specific demethylase 1 (LSD1) metabolically integrates inflammatory osteoclastogenesis and bone resorption in a state of inflammatory arthritis. LSD1-specific inhibitors and gene silencing with small interfering RNAs were used to inhibit the expression of LSD1 in human osteoclast precursor cells derived from CD14-positive monocytes, with subsequent assessment by RNA-sequencing analysis. In experimental mouse models of arthritis, inflammatory osteolysis, or osteoporosis, features of accelerated bone loss and inflammatory osteolysis were analyzed. Furthermore, in blood samples from patients with RA, cis-acting expression quantitative trait loci (cis-eQTL) were analyzed for association with the expression of hypoxia-inducible factor 1α (HIF-1α), and associations between HIF-1α allelic variants and extent of bone erosion were evaluated. In human osteoclast precursor cells, RANKL induced the expression of LSD1 in a mechanistic target of rapamycin-dependent manner. Expression of LSD1 was higher in synovium from RA patients than in synovium from osteoarthritis patients. Inhibition of LSD1 in human osteoclast precursors suppressed osteoclast differentiation. Results of transcriptome analysis identified several LSD1-mediated hypoxia and cell-cycle pathways as key genetic pathways involved in human osteoclastogenesis. Furthermore, HIF-1α protein, which is rapidly degraded by the proteasome in a normoxic environment, was found to be expressed in RANKL-stimulated osteoclast precursor cells. Induction of LSD1 by RANKL stabilized the expression of HIF-1α protein, thereby promoting glycolysis, in conjunction with up-regulation of the transcription factor E2F1. Analyses of cis-eQTL revealed that higher HIF-1α expression was associated with increased bone erosion in patients with RA. Inhibition of LSD1 decreased pathologic bone resorption in mice, both in models of accelerated osteoporosis and models of arthritis and inflammatory osteolysis. LSD1 metabolically regulates osteoclastogenesis in an energy-demanding inflammatory environment. These findings provide potential new therapeutic strategies targeting osteoclasts in the management of inflammatory arthritis, including in patients with RA.
Author Ito, Hiromu
Ito, Shuji
Murata, Koichi
Park‐Min, Kyung‐Hyun
Ivashkiv, Lionel B.
Tanaka, Masao
Matsuda, Shuichi
Terao, Chikashi
Murotani, Yoshiki
Umemoto, Akio
Murakami, Kosaku
Nishitani, Kohei
Watanabe, Ryu
Fujii, Takayuki
Hashimoto, Motomu
Ishie, Shinichiro
Yoshitomi, Hiroyuki
Doi, Kohei
Suzuki, Akari
Morinobu, Akio
Author_xml – sequence: 1
  givenname: Kohei
  surname: Doi
  fullname: Doi, Kohei
  organization: Kyoto University Graduate School of Medicine
– sequence: 2
  givenname: Koichi
  orcidid: 0000-0002-7896-3937
  surname: Murata
  fullname: Murata, Koichi
  email: kchm@kuhp.kyoto-u.ac.jp
  organization: Kyoto University Graduate School of Medicine, Kyoto, Japan, and Hospital for Special Surgery
– sequence: 3
  givenname: Shuji
  surname: Ito
  fullname: Ito, Shuji
  organization: RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, and Shimane University Faculty of Medicine
– sequence: 4
  givenname: Akari
  surname: Suzuki
  fullname: Suzuki, Akari
  organization: RIKEN Center for Integrative Medical Sciences
– sequence: 5
  givenname: Chikashi
  surname: Terao
  fullname: Terao, Chikashi
  organization: RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, and Shizuoka General Hospital and University of Shizuoka
– sequence: 6
  givenname: Shinichiro
  surname: Ishie
  fullname: Ishie, Shinichiro
  organization: Kyoto University Graduate School of Medicine
– sequence: 7
  givenname: Akio
  surname: Umemoto
  fullname: Umemoto, Akio
  organization: Kyoto University Graduate School of Medicine
– sequence: 8
  givenname: Yoshiki
  surname: Murotani
  fullname: Murotani, Yoshiki
  organization: Kyoto University Graduate School of Medicine
– sequence: 9
  givenname: Kohei
  surname: Nishitani
  fullname: Nishitani, Kohei
  organization: Kyoto University Graduate School of Medicine
– sequence: 10
  givenname: Hiroyuki
  surname: Yoshitomi
  fullname: Yoshitomi, Hiroyuki
  organization: Kyoto University Graduate School of Medicine
– sequence: 11
  givenname: Takayuki
  surname: Fujii
  fullname: Fujii, Takayuki
  organization: Kyoto University Graduate School of Medicine
– sequence: 12
  givenname: Ryu
  orcidid: 0000-0002-1089-5296
  surname: Watanabe
  fullname: Watanabe, Ryu
  organization: Kyoto University Graduate School of Medicine
– sequence: 13
  givenname: Motomu
  surname: Hashimoto
  fullname: Hashimoto, Motomu
  organization: Kyoto University Graduate School of Medicine
– sequence: 14
  givenname: Kosaku
  surname: Murakami
  fullname: Murakami, Kosaku
  organization: Kyoto University Graduate School of Medicine
– sequence: 15
  givenname: Masao
  surname: Tanaka
  fullname: Tanaka, Masao
  organization: Kyoto University Graduate School of Medicine
– sequence: 16
  givenname: Hiromu
  orcidid: 0000-0002-1827-382X
  surname: Ito
  fullname: Ito, Hiromu
  organization: Kyoto University Graduate School of Medicine
– sequence: 17
  givenname: Kyung‐Hyun
  surname: Park‐Min
  fullname: Park‐Min, Kyung‐Hyun
  organization: Hospital for Special Surgery
– sequence: 18
  givenname: Lionel B.
  surname: Ivashkiv
  fullname: Ivashkiv, Lionel B.
  organization: Hospital for Special Surgery
– sequence: 19
  givenname: Akio
  surname: Morinobu
  fullname: Morinobu, Akio
  organization: Kyoto University Graduate School of Medicine
– sequence: 20
  givenname: Shuichi
  surname: Matsuda
  fullname: Matsuda, Shuichi
  organization: Kyoto University Graduate School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35077015$$D View this record in MEDLINE/PubMed
BookMark eNp90U1u1DAUB_AIFdFSuuACyBIbWEzrjzgfy34NHWlQpWFYR47zPOPKsYPtCLLjCBwFLsIhOAlmpmVRCbyxZf_e019-z7MD6yxk2UuCTwnG9Ez4eJpTXOZPsiPKaDHjFPODhzOpyWF2EsIdTqsucYH5s-yQcVyWmPCj7PvKGUBOoeUUtIVfX799GEBqpSW6gh7idjIiACJIW_Qeomid0VIYM6GFjbDxImq7QbchgpNJRnSllQIPNur05CwStktUGdH3Ijo_oYsUH60gOD_swHrr3bjZoptpcF-0SAkWthulblOuuZCpBpGfP3Z9rumcvMieKmECnNzvx9nH-fX68ma2vH23uDxfziSrqnzWdZwWslKtqqGFkghVsJyxTha1IqXMc55XWDHWyiKvOEjg6aKUHQdVl3kF7Dh7s-87ePdphBCbXgcJxggLbgwNLSgteE04S_T1I3rnRm9TuqRKwgmpC5zUq3s1tj10zeB1L_zUPMwigbd7IL0LwYP6Swhu_oy6SaNudqNO9uyRlTruPjx6oc3_Kj5rA9O_Wzfnq_W-4jcyqr4g
CitedBy_id crossref_primary_10_3389_fcimb_2025_1529692
crossref_primary_10_1186_s13075_023_03007_9
crossref_primary_10_1016_j_intimp_2022_109095
crossref_primary_10_1016_j_jphs_2023_09_005
crossref_primary_10_1002_advs_202403177
crossref_primary_10_1111_jcmm_70398
crossref_primary_10_1007_s10787_024_01552_6
crossref_primary_10_1002_jcp_30844
crossref_primary_10_1016_j_bioorg_2024_107603
crossref_primary_10_1016_j_heliyon_2024_e31314
crossref_primary_10_1016_j_bone_2024_117382
crossref_primary_10_1038_s41413_025_00413_4
crossref_primary_10_1038_s44324_024_00010_9
crossref_primary_10_1016_j_acthis_2023_152073
crossref_primary_10_3390_molecules29133191
crossref_primary_10_1080_08820139_2024_2337025
crossref_primary_10_1177_00368504241300723
crossref_primary_10_1177_09603271241269028
crossref_primary_10_3390_cells11223552
crossref_primary_10_1021_acschembio_3c00386
crossref_primary_10_3390_biomedicines12102292
crossref_primary_10_3390_md22020095
crossref_primary_10_1038_s41419_024_06521_z
crossref_primary_10_3389_fimmu_2022_930244
crossref_primary_10_1016_j_intimp_2025_114017
crossref_primary_10_3389_fphys_2022_939253
crossref_primary_10_1016_j_biopha_2023_115646
crossref_primary_10_1016_j_freeradbiomed_2025_01_013
crossref_primary_10_1016_j_ijbiomac_2025_141807
crossref_primary_10_3892_ijmm_2022_5197
crossref_primary_10_1039_D3MA00733B
crossref_primary_10_1016_j_gendis_2024_101307
crossref_primary_10_3390_ijms24043605
crossref_primary_10_1186_s12891_025_08274_y
crossref_primary_10_1038_s42003_024_06581_z
crossref_primary_10_1007_s11033_024_09353_4
crossref_primary_10_2147_IJN_S456533
crossref_primary_10_1093_jbmrpl_ziae142
crossref_primary_10_1016_j_apsb_2024_01_005
crossref_primary_10_1016_j_phrs_2024_107537
crossref_primary_10_3390_biom15010071
Cites_doi 10.1136/annrheumdis-2018-214827
10.1038/nm.3815
10.1038/onc.2017.158
10.1111/imr.12841
10.1002/med.21350
10.1038/nature06905
10.1158/1535-7163.MCT-18-0373
10.1016/j.biocel.2016.08.034
10.1007/s00774-006-0725-9
10.1038/nrrheum.2017.213
10.1182/blood-2012-01-405993
10.1016/j.immuni.2017.06.018
10.1002/jcp.22798
10.1186/s12881-019-0767-1
10.1021/jm400870h
10.1002/jbmr.1976
10.1038/s41413-018-0015-x
10.1038/s41577-019-0178-8
10.1186/s13045-019-0811-9
10.1016/j.immuni.2014.09.008
10.1007/s00018-020-03489-9
10.1016/j.bbagrm.2019.03.004
10.1038/nm.3774
10.1016/j.biocel.2004.08.012
10.1084/jem.20112607
10.1172/JCI93356
10.1038/ng.3885
10.1172/JCI89935
10.1002/art.40504
10.1038/ncomms10347
10.1056/NEJMcp1513724
10.1016/j.jmb.2016.10.004
10.1007/s00281-019-00757-0
10.1038/leu.2014.119
10.1111/cas.13990
10.1038/s42255-020-00318-y
10.1172/JCI26132
10.1016/j.cmet.2014.07.011
ContentType Journal Article
Copyright 2022 American College of Rheumatology
2022 American College of Rheumatology.
Copyright_xml – notice: 2022 American College of Rheumatology
– notice: 2022 American College of Rheumatology.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T5
7TM
7U7
C1K
H94
K9.
7X8
DOI 10.1002/art.42074
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Toxicology Abstracts
Bacteriology Abstracts (Microbiology B)
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Calcium & Calcified Tissue Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Toxicology Abstracts
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2326-5205
EndPage 960
ExternalDocumentID 35077015
10_1002_art_42074
ART42074
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Japan Society for the Promotion of Science
  funderid: 17H06816; 18H02926
– fundername: Inamori Foundation
– fundername: Kanae Foundation for the Promotion of Medical Science
– fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases
  funderid: DE019420
– fundername: Takeda Science Foundation
– fundername: NIDCR NIH HHS
  grantid: R01 DE019420
– fundername: NIAMS NIH HHS
  grantid: DE019420
GroupedDBID 0R~
1OC
24P
33P
3SF
4.4
52O
52U
52V
53G
5VS
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAQQT
AASGY
AAWTL
AAXRX
AAYCA
AAZKR
ABCUV
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZFZN
AZVAB
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
DCZOG
DIK
DRFUL
DRMAN
DRSTM
EBS
EJD
EMOBN
EX3
F00
FUBAC
G-S
G.N
GODZA
HGLYW
KBYEO
LATKE
LEEKS
LH4
LITHE
LOXES
LUTES
LW6
LYRES
MEWTI
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
NF~
O66
O9-
OK1
OVD
P2W
PQQKQ
QB0
ROL
SUPJJ
SV3
TEORI
V9Y
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WVDHM
WXSBR
YCJ
AAFWJ
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7T5
7TM
7U7
C1K
H94
K9.
7X8
ID FETCH-LOGICAL-c3884-dd526c8fbf9ebe71af63433dc69f17c445480f33bc6485ece55487cd5ef9748e3
ISSN 2326-5191
2326-5205
IngestDate Fri Jul 11 08:38:59 EDT 2025
Fri Jul 25 12:29:17 EDT 2025
Mon Jul 21 05:44:24 EDT 2025
Tue Jul 01 00:56:05 EDT 2025
Thu Apr 24 22:54:59 EDT 2025
Wed Jan 22 16:26:09 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License 2022 American College of Rheumatology.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c3884-dd526c8fbf9ebe71af63433dc69f17c445480f33bc6485ece55487cd5ef9748e3
Notes Dr. Murata's work was supported by the KANAE Foundation for the Promotion of Medical Science, Takeda Science Foundation, Inamori Foundation, and JSPS KAKENHI (grants 17H06816 and 18H02926). Research conducted in the US at the Hospital for Special Surgery was supported by the NIH (grant DE‐019420).
.
Author disclosures are available at
https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fart.42074&file=art42074‐sup‐0001‐Disclosureform.pdf
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-7896-3937
0000-0002-1089-5296
0000-0002-1827-382X
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/9156537
PMID 35077015
PQID 2671511960
PQPubID 946334
PageCount 13
ParticipantIDs proquest_miscellaneous_2622659153
proquest_journals_2671511960
pubmed_primary_35077015
crossref_primary_10_1002_art_42074
crossref_citationtrail_10_1002_art_42074
wiley_primary_10_1002_art_42074_ART42074
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2022
2022-06-00
20220601
PublicationDateYYYYMMDD 2022-06-01
PublicationDate_xml – month: 06
  year: 2022
  text: June 2022
PublicationDecade 2020
PublicationPlace Boston, USA
PublicationPlace_xml – name: Boston, USA
– name: United States
– name: Atlanta
PublicationTitle Arthritis & rheumatology (Hoboken, N.J.)
PublicationTitleAlternate Arthritis Rheumatol
PublicationYear 2022
Publisher Wiley Periodicals, Inc
Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Periodicals, Inc
– name: Wiley Subscription Services, Inc
References 2015; 35
2012; 120
2013; 28
2017; 47
2017; 49
2019; 78
2005; 115
2019; 12
2019; 19
2020; 77
2014; 28
2014; 41
2012; 227
2016; 79
2014; 20
2019; 1862
2012; 209
2018; 6
2017; 429
2016; 7
2018; 17
2020; 2
2019; 20
2019; 41
2017; 36
2020; 294
2013; 56
2015; 21
2018; 70
2020; 26
2016; 374
2005; 37
2008; 453
2018; 11
2017; 127
2007; 25
2018; 14
2019; 110
e_1_2_8_28_1
e_1_2_8_29_1
e_1_2_8_24_1
e_1_2_8_25_1
e_1_2_8_26_1
e_1_2_8_27_1
e_1_2_8_3_1
e_1_2_8_2_1
e_1_2_8_5_1
e_1_2_8_4_1
e_1_2_8_7_1
e_1_2_8_9_1
e_1_2_8_8_1
e_1_2_8_20_1
e_1_2_8_21_1
e_1_2_8_22_1
e_1_2_8_23_1
Liu W (e_1_2_8_39_1) 2018; 11
e_1_2_8_41_1
e_1_2_8_40_1
e_1_2_8_17_1
e_1_2_8_18_1
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_16_1
e_1_2_8_37_1
Tsourdi E (e_1_2_8_6_1) 2020; 26
e_1_2_8_32_1
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_30_1
References_xml – volume: 56
  start-page: 9496
  year: 2013
  end-page: 508
  article-title: High‐throughput virtual screening identifies novel N’‐(1‐phenylethylidene)‐benzohydrazides as potent, specific, and reversible LSD1 inhibitors
  publication-title: J Med Chem
– volume: 28
  start-page: 2392
  year: 2013
  end-page: 9
  article-title: Metabolic regulation of osteoclast differentiation and function
  publication-title: J Bone Miner Res
– volume: 21
  start-page: 281
  year: 2015
  end-page: 7
  article-title: DNA methyltransferase 3a regulates osteoclast differentiation by coupling to an S‐adenosylmethionine‐producing metabolic pathway
  publication-title: Nat Med
– volume: 26
  year: 2020
  article-title: Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS
  publication-title: J Clin Endocrinol Metab
– volume: 49
  start-page: 1120
  year: 2017
  end-page: 5
  article-title: Polygenic burdens on cell‐specific pathways underlie the risk of rheumatoid arthritis
  publication-title: Nat Genet
– volume: 127
  start-page: 2030
  year: 2017
  end-page: 9
  article-title: Inflammatory osteolysis: a conspiracy against bone
  publication-title: J Clin Invest
– volume: 12
  start-page: 129
  year: 2019
  article-title: LSD1/KDM1A inhibitors in clinical trials: advances and prospects
  publication-title: J Hematol Oncol
– volume: 6
  start-page: 14
  year: 2018
  article-title: Histone demethylase LSD1 regulates bone mass by controlling WNT7B and BMP2 signaling in osteoblasts
  publication-title: Bone Res
– volume: 70
  start-page: 984
  year: 2018
  end-page: 99
  article-title: Synovial cell metabolism and chronic inflammation in rheumatoid arthritis [review]
  publication-title: Arthritis Rheumatol
– volume: 110
  start-page: 1510
  year: 2019
  end-page: 7
  article-title: Hypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer [review]
  publication-title: Cancer Sci
– volume: 227
  start-page: 514
  year: 2012
  end-page: 24
  article-title: Functional regulation of HIF‐1α under normoxia—is there more than post‐translational regulation?
  publication-title: J Cell Physiol
– volume: 41
  start-page: 565
  year: 2019
  end-page: 72
  article-title: Metabolic reprogramming in osteoclasts
  publication-title: Semin Immunopathol
– volume: 115
  start-page: 3418
  year: 2005
  end-page: 27
  article-title: M‐CSF mediates TNF‐induced inflammatory osteolysis
  publication-title: J Clin Invest
– volume: 120
  start-page: 3118
  year: 2012
  end-page: 25
  article-title: Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia‐inducible factor 1 α
  publication-title: Blood
– volume: 209
  start-page: 2441
  year: 2012
  end-page: 53
  article-title: PDK1 regulation of mTOR and hypoxia‐inducible factor 1 integrate metabolism and migration of CD8+ T cells
  publication-title: J Exp Med
– volume: 77
  start-page: 3341
  year: 2020
  end-page: 50
  article-title: Biological roles of LSD1 beyond its demethylase activity
  publication-title: Cell Mol Life Sci
– volume: 453
  start-page: 807
  year: 2008
  end-page: 11
  article-title: NF‐κB links innate immunity to the hypoxic response through transcriptional regulation of HIF‐1α
  publication-title: Nature
– volume: 1862
  start-page: 535
  year: 2019
  end-page: 46
  article-title: Inhibition of lysine‐specific demethylase LSD1 induces senescence in glioblastoma cells through a HIF‐1alpha‐dependent pathway
  publication-title: Biochim Biophys Acta Gene Regul Mech
– volume: 374
  start-page: 254
  year: 2016
  end-page: 62
  article-title: Clinical practice: postmenopausal osteoporosis
  publication-title: N Engl J Med
– volume: 78
  start-page: 899
  year: 2019
  end-page: 907
  article-title: Effects of the anti‐RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease‐modifying antirheumatic drugs (DESIRABLE study): a randomised, double‐blind, placebo‐controlled phase 3 trial
  publication-title: Ann Rheum Dis
– volume: 2
  start-page: 1382
  year: 2020
  end-page: 90
  article-title: Stepwise cell fate decision pathways during osteoclastogenesis at single‐cell resolution
  publication-title: Nat Metab
– volume: 28
  start-page: 2155
  year: 2014
  end-page: 64
  article-title: Highly effective combination of LSD1 (KDM1A) antagonist and pan‐histone deacetylase inhibitor against human AML cells
  publication-title: Leukemia
– volume: 20
  start-page: 483
  year: 2014
  end-page: 98
  article-title: Mitochondrial complex I activity suppresses inflammation and enhances bone resorption by shifting macrophage‐osteoclast polarization
  publication-title: Cell Metab
– volume: 11
  start-page: 333
  year: 2018
  end-page: 41
  article-title: Knockdown of LSD1 ameliorates the severity of rheumatoid arthritis and decreases the function of CD4 T cells in mouse models
  publication-title: Int J Clin Exp Pathol
– volume: 21
  start-page: 212
  year: 2015
  end-page: 3
  article-title: Metabolic‐epigenetic coupling in osteoclast differentiation
  publication-title: Nat Med
– volume: 37
  start-page: 535
  year: 2005
  end-page: 40
  article-title: Hypoxia‐inducible factor 1: regulation by hypoxic and non‐hypoxic activators
  publication-title: Int J Biochem Cell Biol
– volume: 41
  start-page: 518
  year: 2014
  end-page: 28
  article-title: HIF transcription factors, inflammation, and immunity
  publication-title: Immunity
– volume: 7
  start-page: 10347
  year: 2016
  article-title: Methylation‐dependent regulation of HIF‐1α stability restricts retinal and tumour angiogenesis
  publication-title: Nat Commun
– volume: 17
  start-page: 1902
  year: 2018
  end-page: 16
  article-title: Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP‐2509 engages the endoplasmic reticulum stress response
  publication-title: Mol Cancer Ther
– volume: 294
  start-page: 164
  year: 2020
  end-page: 76
  article-title: Impaired T cell receptor signaling and development of T cell‐mediated autoimmune arthritis [review]
  publication-title: Immunol Rev
– volume: 19
  start-page: 626
  year: 2019
  end-page: 42
  article-title: Osteoimmunology: evolving concepts in bone‐immune interactions in health and disease [review]
  publication-title: Nat Rev Immunol
– volume: 14
  start-page: 146
  year: 2018
  end-page: 56
  article-title: Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity [review]
  publication-title: Nat Revi Rheumatol
– volume: 35
  start-page: 1032
  year: 2015
  end-page: 71
  article-title: A systematic review of histone lysine‐specific demethylase 1 and its inhibitors
  publication-title: Med Res Rev
– volume: 429
  start-page: 2055
  year: 2017
  end-page: 65
  article-title: Systematic analysis of known and candidate lysine demethylases in the regulation of myoblast differentiation
  publication-title: J Mol Biol
– volume: 20
  start-page: 37
  year: 2019
  article-title: HIF‐1 transcription activity: HIF1A driven response in normoxia and in hypoxia
  publication-title: BMC Med Genet
– volume: 127
  start-page: 2555
  year: 2017
  end-page: 68
  article-title: MYC‐dependent oxidative metabolism regulates osteoclastogenesis via nuclear receptor ERRα
  publication-title: J Clin Invest
– volume: 47
  start-page: 66
  year: 2017
  end-page: 79
  article-title: Hypoxia‐sensitive COMMD1 integrates signaling and cellular metabolism in human macrophages and suppresses osteoclastogenesis
  publication-title: Immunity
– volume: 25
  start-page: 36
  year: 2007
  end-page: 45
  article-title: Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood
  publication-title: J Bone Miner Metab
– volume: 79
  start-page: 168
  year: 2016
  end-page: 80
  article-title: Energy metabolism in osteoclast formation and activity
  publication-title: Int J Biochem Cell Biol
– volume: 36
  start-page: 5512
  year: 2017
  end-page: 21
  article-title: LSD1 demethylates HIF1α to inhibit hydroxylation and ubiquitin‐mediated degradation in tumor angiogenesis
  publication-title: Oncogene
– ident: e_1_2_8_5_1
  doi: 10.1136/annrheumdis-2018-214827
– ident: e_1_2_8_14_1
  doi: 10.1038/nm.3815
– ident: e_1_2_8_20_1
  doi: 10.1038/onc.2017.158
– ident: e_1_2_8_23_1
  doi: 10.1111/imr.12841
– ident: e_1_2_8_33_1
  doi: 10.1002/med.21350
– ident: e_1_2_8_27_1
  doi: 10.1038/nature06905
– ident: e_1_2_8_41_1
  doi: 10.1158/1535-7163.MCT-18-0373
– ident: e_1_2_8_10_1
  doi: 10.1016/j.biocel.2016.08.034
– ident: e_1_2_8_19_1
  doi: 10.1007/s00774-006-0725-9
– ident: e_1_2_8_3_1
  doi: 10.1038/nrrheum.2017.213
– ident: e_1_2_8_25_1
  doi: 10.1182/blood-2012-01-405993
– ident: e_1_2_8_15_1
  doi: 10.1016/j.immuni.2017.06.018
– ident: e_1_2_8_29_1
  doi: 10.1002/jcp.22798
– ident: e_1_2_8_30_1
  doi: 10.1186/s12881-019-0767-1
– ident: e_1_2_8_40_1
  doi: 10.1021/jm400870h
– ident: e_1_2_8_12_1
  doi: 10.1002/jbmr.1976
– ident: e_1_2_8_37_1
  doi: 10.1038/s41413-018-0015-x
– ident: e_1_2_8_7_1
  doi: 10.1038/s41577-019-0178-8
– ident: e_1_2_8_34_1
  doi: 10.1186/s13045-019-0811-9
– ident: e_1_2_8_16_1
  doi: 10.1016/j.immuni.2014.09.008
– ident: e_1_2_8_17_1
  doi: 10.1007/s00018-020-03489-9
– ident: e_1_2_8_21_1
  doi: 10.1016/j.bbagrm.2019.03.004
– ident: e_1_2_8_9_1
  doi: 10.1038/nm.3774
– ident: e_1_2_8_24_1
  doi: 10.1016/j.biocel.2004.08.012
– ident: e_1_2_8_26_1
  doi: 10.1084/jem.20112607
– ident: e_1_2_8_2_1
  doi: 10.1172/JCI93356
– ident: e_1_2_8_22_1
  doi: 10.1038/ng.3885
– ident: e_1_2_8_8_1
  doi: 10.1172/JCI89935
– ident: e_1_2_8_38_1
  doi: 10.1002/art.40504
– ident: e_1_2_8_32_1
  doi: 10.1038/ncomms10347
– ident: e_1_2_8_4_1
  doi: 10.1056/NEJMcp1513724
– ident: e_1_2_8_36_1
  doi: 10.1016/j.jmb.2016.10.004
– ident: e_1_2_8_13_1
  doi: 10.1007/s00281-019-00757-0
– ident: e_1_2_8_35_1
  doi: 10.1038/leu.2014.119
– ident: e_1_2_8_28_1
  doi: 10.1111/cas.13990
– ident: e_1_2_8_31_1
  doi: 10.1038/s42255-020-00318-y
– volume: 11
  start-page: 333
  year: 2018
  ident: e_1_2_8_39_1
  article-title: Knockdown of LSD1 ameliorates the severity of rheumatoid arthritis and decreases the function of CD4 T cells in mouse models
  publication-title: Int J Clin Exp Pathol
– ident: e_1_2_8_18_1
  doi: 10.1172/JCI26132
– ident: e_1_2_8_11_1
  doi: 10.1016/j.cmet.2014.07.011
– volume: 26
  start-page: dgaaa756
  year: 2020
  ident: e_1_2_8_6_1
  article-title: Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS
  publication-title: J Clin Endocrinol Metab
SSID ssj0000970605
Score 2.5612166
Snippet Objective Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It...
Hypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It alleviates...
ObjectiveHypoxia occurs in tumors, infections, and sites of inflammation, such as in the affected joints of patients with rheumatoid arthritis (RA). It...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 948
SubjectTerms Animal models
Animals
Arthritis
Arthritis, Rheumatoid
Biomedical materials
Bone loss
Bone resorption
Bone Resorption - metabolism
Bone Resorption - pathology
CD14 antigen
Cell Differentiation
Cell Hypoxia
Differentiation
E2F1 Transcription Factor - metabolism
Evaluation
Gene mapping
Gene regulation
Gene sequencing
Gene silencing
Glycolysis
Histone Demethylases - genetics
Histone Demethylases - metabolism
Humans
Hypoxia
Hypoxia-Inducible Factor 1, alpha Subunit - metabolism
Inflammation
Joint diseases
Lysine
Mice
Monocytes
Osteoarthritis
Osteoclastogenesis
Osteoclasts
Osteoclasts - metabolism
Osteoclasts - pathology
Osteolysis
Osteolysis - metabolism
Osteolysis - pathology
Osteoporosis
Osteoporosis - metabolism
Osteoporosis - pathology
Osteoprogenitor cells
Precursors
Proteasomes
Proteins
Quantitative trait loci
RANK Ligand - metabolism
Rapamycin
Rheumatoid arthritis
Synovium
TOR protein
TRANCE protein
Tumors
Title Role of Lysine‐Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia‐Inducible Factor 1α and E2F1
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fart.42074
https://www.ncbi.nlm.nih.gov/pubmed/35077015
https://www.proquest.com/docview/2671511960
https://www.proquest.com/docview/2622659153
Volume 74
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2326-5205
  dateEnd: 20240929
  omitProxy: true
  ssIdentifier: ssj0000970605
  issn: 2326-5191
  databaseCode: DIK
  dateStart: 19990101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtpAEF3RVKr6UvVe2rTaVkWqhExZr6-PJIBIAonUgMSbZS9r4YZiSm2p5Jv60h_JN3X2gjGBSmlfLGtZvJbOYZiZnZ2D0EduxZy7JDZoaEaGRd3IiAB2Y2K5E86IyahMuA3Ond7IOh3b40rlplS1lGdRg13vPVfyP6jCGOAqTsn-A7LFQ2EA7gFfuALCcL0Txl90aWB_JarXDaklHycMjIgQhl6BY8zrRGQ0BjwDsEV-bjZbySygaBEhsgQXgHLKYGYG1k9ppWQKLV0pHANlvqmt-KN0zmW-f6nszFBr_PRWi_RnEhpCBoQl4ihWV6r41EntuFM7IvJJHYjdy55wa5lNZUMlSb7llOdiFdkQCpzeXhqlV1yfBTttlPIV7VTVH6RTnpTYEiov-CxN2LQYP5EaUfXLaf61GLvMr3Ml1d26CpdJOesBAXNRnaWMIziCDgTRTbUjzveMaeuuNIA0i8um2lcdPnf-QlRLWsC0YZlN_e2tNt3nF0F31O8Hw854WKPdxXdDaJiJvf4abSuS3UP3TddxhKJG--SsyPk1fdGryJZ6h_pV182umubnYsltF2kn7tkOo6QfNHyMHukABrcUG5-gCp8_RQ8GukTjGfolSInTGN8iJS6REhOczPEWKXGJlHhDSnyLlBiohMukxIKUeENKrEmJd0iJFSkxufktnyII-RyNup3hcc_QkiAGo54HJmRimw7z4ij2wfq4JIwdalE6YY4fE5dZlmhfGFMaMcfybM64LSJyNrF5DIGzx-kLdDCH93qFMIk8CKVD8OfBQ3VD5vmx7_kmsynnJqFeFX1aoxAw3S9fyLbMAtXp2wwAsEACVkUfiqkL1SRm36TDNZSBtiE_AtNxidjJd5pV9L74GCy82LYL5zzNxRwIkWwfXJMqeqkoUKxCIZxzwaOHl5Wc-PvyAcTH8ub1HRZ6gx5ufnSH6CBb5vwtON9Z9E4y-g-mKt6G
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+Lysine-Specific+Demethylase+1+in+Metabolically+Integrating+Osteoclast+Differentiation+and+Inflammatory+Bone+Resorption+Through+Hypoxia-Inducible+Factor+1%CE%B1+and+E2F1&rft.jtitle=Arthritis+%26+rheumatology+%28Hoboken%2C+N.J.%29&rft.au=Doi%2C+Kohei&rft.au=Murata%2C+Koichi&rft.au=Ito%2C+Shuji&rft.au=Suzuki%2C+Akari&rft.date=2022-06-01&rft.issn=2326-5205&rft.eissn=2326-5205&rft.volume=74&rft.issue=6&rft.spage=948&rft_id=info:doi/10.1002%2Fart.42074&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2326-5191&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2326-5191&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2326-5191&client=summon